This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cryo-Cell International Affiliate Earns Patent For Processing Umbilical Cord Blood For Therapeutic Use In Treating Neurodegenerative Diseases And Spinal Cord And Brain Injuries

OLDSMAR, Fla., March 15, 2013 (GLOBE NEWSWIRE) -- A patent issued to Saneron CCEL Therapeutics, Inc. and the University of South Florida may facilitate increased use of cord blood stem cells in medical therapies, according to Linda Kelley, Ph.D., chief scientific officer with Cryo-Cell International (OTCQB:CCEL). Cryo-Cell is a major investor in Saneron CCEL Therapeutics, a Tampa, Fla.-based research firm with rights to 20 patents related to their cellular therapy technology. 

A human umbilical cord is a rich source of hematopoietic stem cells that can differentiate and give rise to all blood cell types. The patent was awarded for a method of retrieval, incubation and transplantation of cells derived from umbilical cord blood, which can be used to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, multiple sclerosis and Alzheimer's as well as spinal cord and brain injuries. The patented method has the potential to treat heart attacks and cardiovascular diseases as well.

 "This patent means that cord blood stem cells can now be used to treat neurological conditions for which there are few alternatives. Too often these valuable cells are disposed of as medical waste," Dr. Kelley explained.

"Umbilical cord blood stem cells provide an advantage over stem cells derived from bone marrow because they are easier to obtain," said Nicole Kuzmin-Nichols, Saneron president and COO.

 "A single cord blood sample provides enough hematopoietic stem cells to provide short and long-term engraftment with a low incidence of graft-versus-host disease," said Dr. Alison E. Willing, professor, Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, University of South Florida and an inventor on the patent. "

"Our partnership with Saneron CCEL and the firm's many talented researchers sets Cryo-Cell apart from most stem cell banks which focus on storage. We believe that, through our interest in Saneron, Cryo-Cell holds more patents related to cord blood banking than any other cord blood bank. We are on the forefront of regenerative medicine," said David Portnoy, Cryo-Cell chairman and co-CEO. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs